

Feline Immunodeficiency virus gp95 antibody [SU1-30]

Cat. No. GTX41153

Host	Mouse
Clonality	Monoclonal
Isotype	lgG1
Applications	WB, FCM, Neutralizing/Inhibition
Reactivity	Feline Immunodeficiency Virus

Package 250 μg

Applications

Application Note

 ${}^{\star}\text{Optimal dilutions/concentrations}$ should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Assay dependent
FCM	Assay dependent
Neutralizing/Inhibition	Assay dependent

Note: Mouse anti Feline Immunodeficiency Virus gp95 antibody, clone SU1-30 has been shown to inhibit the sCD134-activated entry of both clade B and clade C FIV strains (de Parseval, A. et al. 2006).

Not tested in other applications.

Product Note

This antibody recognizes the relatively conserved E60 peptide (amino acid sequence SSWKQRNRWEWRPDF) located within the V3 region of FIV (Feline Immunodeficiency Virus) envelope glycoprotein SU,gp95. Clone SU1-30 does not recognise Feline Leukaemia Virus, Feline Herpes Virus type 1, Feline Coronavirus or Feline Calicivirus.

Properties	
Form	Liquid
Buffer	PBS
Preservative	0.05% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	1.0 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	This antibody recognizes the relatively conserved E60 peptide (amino acid sequence SSWKQRNRWEWRPDF) located within the V3 region of FIV (Feline Immunodeficiency Virus) envelope glycoprotein SU,gp95.
Purification	Protein A purified From tissue culture supernatant
Conjugation	Unconjugated



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 12 / 16 Page 1 of 2



For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Note

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 12 / 16 Page 2 of 2